Scientific Report

2014
Our motto is dynamic, our aim is firm, and our determination unremitting.

I recovered from leukaemia thanks to the extraordinary work of the doctors and nurses who looked after me. Like many grateful patients, I also benefited from the perseverance of scientists searching for a cure for this disease.

Since the day we were established we have always offered financial assistance for research, through grants, university funding and, mainly, by providing funding for projects and the creation of laboratories and other scientific infrastructures.

We can not stop until leukaemia becomes a totally curable disease. The creation of the Josep Carreras Leukaemia Research Institute is the latest sign of what drives us forward: our unceasing determination to battle against this disease until we defeat it.

Thanks to the extraordinary team of doctors, experts in life sciences, the support of the Generalitat de Catalunya, and the solidarity of our generous donors, our Institute is now a reality.

I would like to thank you for your interest in our institution and invite you to join us in our crusade.

Josep Carreras
President Board of Trustees
Josep Carreras Leukaemia Research Institute (IJC)
Contents
About us

Welcome
Who we are and what we do
Mission, vision and values

Our team

Governing bodies
Organisational chart
Human resources

Financial data

Scientific activities

Income statement
Balance sheet
Fundraising

Scientific production

Research groups
Research projects
Technology platforms
Clinical trials
Innovation and transferability

Training activities

Graduate and post-graduate
Theses read
Seminars and sessions
Courses and congresses

Cooperation

Agreements
Institutions involved

Communication

Scientific dissemination
Institutional events

Upcoming challenges

Phase 1 of the new BDN building
Mission, vision, values
About us
Welcome

Once again the IJC’s annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2014 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

A centre totally capable of synchronising research, health care, innovation and teaching, something of fundamental importance for achieving scientific excellence.

Highlights of the IJC’s leadership are the construction of the new building in Badalona and the agreements about the SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC).

With all this in mind, I would like to invite you to discover more from the following pages about the activities in 2014, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu
President of the Delegate Committee
Josep Carreras Leukaemia Research Institute (IJC)
Who we are and what we do

The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.

The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the research facilities of Barcelona’s Hospital Clínic, and those of the University of Barcelona (UB) Faculty of Medicine; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit; and thirdly, the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB’s Sant Pau teaching unit. The IJC's Hospital Clínic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clinic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.
Mission

Our mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases.

Vision

The Josep Carreras Leukaemia Research Institute's vision is for the research it does to identify new therapeutic targets that will make it possible to develop more precise and less aggressive treatments. We aspire to understanding the origin and development of leukaemias and other malignant blood diseases in order to prevent them. We are working so that, in the future, all leukaemias will be curable.

Values

We are inspired by the example of Josep Carreras and the professional staff he has chosen to found the Institute that bears his name. Financial donations, be they public or private, are used in the most efficient way by simplifying administrative procedures and reducing the secondary costs of our main mission.

We protect the dignity and respect the rights of everyone who has a relationship with the Institute, especially those who collaborate on our projects. Our work is as stalwart as the patients and families who participate in the project, and our sponsors and staff.

We will continue until all leukaemias can be cured.

We take full advantage of all possible synergies, we promote continuing cooperation, the creation of new alliances and group work. We also promote the dissemination of information about leukaemia and encourage citizen participation.

We aspire to attracting, promoting and creating talent.
Our team
The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clinic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (iCERCA).

**Board of Trustees**

**President**

**Mr. Josep Carreras Coll**
President of the Josep Carreras Foundation and the Josep Carreras Leukaemia Research Institute

**First Vice-president**
Catalan Government Minister of Business and Knowledge

**Second Vice-president**
Catalan Government Minister of Health

**Members**
Rector Autonomous University of Barcelona (UAB)
Rector University of Barcelona (UB)
Mayor of Badalona

**Director General for Research, Catalan Government Ministry of Business and Knowledge**

**Director General for Health Research and Planning**

**Deputy Director General for Health Research and Innovation**

**Director General Catalan Institute of Oncology**

**Administrator Northern Metropolitan Territorial Area**

**Secretary for Universities and Research, Catalan Government Ministry of Business and Knowledge**

**Director Catalan Foundation for Research and Innovation**

**Research Director Hospital Clinic - IDIBAPS**

**Treasurer of the Josep Carreras Leukaemia Foundation**

**Vice-president of the Josep Carreras Leukaemia Foundation**

**Trustee of the Josep Carreras Leukaemia Foundation**

**Administrator of the Josep Carreras Leukaemia Foundation**

**Vice-rector for Research and Transferability, Autonomous University of Barcelona (UAB)**

**University of Barcelona Hospital Coordination Committee**

**Secretary**

**Director of the Research Centres of Catalonia Institution Foundation (iCERCA)**
Delegate committee

President
**Prof. Evarist Feliu**, Coordinator of the ICO-Germans Trias i Pujol Campus

Members
PRICS coordinator, Catalan Government Ministry of Health
Director General, Catalan Government Ministry of Health, Directorate General Health Resources Planning Regulation
Directorate General for Research, Catalan Government Ministry of Business and Knowledge
Director iCerca, CERCA Institution, Research Centres of Catalonia
Administrator, Josep Carreras International Foundation
University of Barcelona Commissioner for Hospital Coordination
Vice-rector for Strategic Projects and Planning, Autonomous University of Barcelona

Co-External Scientific Committee

President
Prof. Lucio Luzzatto, Instituto Toscano Tumori Firenze

Members
Prof. Robert Sackstein, Dana-Farber/Harvard Cancer Center Boston
Prof. Francesco Lococo, Università degli Studi di Roma "Tor Vergata"
Prof. Alberto Orfao, CIC Centro de Investigación del Cáncer Salamanca.
Prof. Brigitte Schlegelberger, University of Hannover

Internal Scientific Committee

UB-Clinic Campus
Álvaro Urbano Ispizúa (Internal Scientific Committee Coordinator)
Pablo Menéndez (Campus Research Director)
Jordi Esteve Reyner
Armando López Guillermo
Joan Bladé Creixentí
Francisco Cervantes Requena

ICO-GTIP Campus
Evarist Feliu Frasnedo (President of the Delegate Committee)
Francesc Solé (Campus Research Director)
Josep Mª Ribera Santasusana
Lurdes Zamora Plana
José Tomás Navarro Ferrando
Juan Manuel Sancho Cía

Sant Pau Campus
Jordi Sierra
Josep Nomdedeu
Joan Carles Souto
Ramon Mangues
Carol Moreno
Organisational chart

Scientific directors

Campus ICO-GTP
Francesc Solé

Campus Clinic-UB
Pablo Menéndez

Campus Sant Pau
Jordi Sierra
<table>
<thead>
<tr>
<th>Category</th>
<th>IJC ICO</th>
<th>IJC Clinic UB</th>
<th>IJC Sant Pau UAB</th>
<th>IJC Shared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germans Trias UAB</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-doctoral researchers</td>
<td>2</td>
<td>11</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Post-doctoral researchers</td>
<td>2</td>
<td>5</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Support staff</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Management and administration</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>Staff professionally linked</td>
<td>12</td>
<td>21</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>with the IJC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff professionally linked</td>
<td>28</td>
<td>14</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>with the Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Germans Trias UAB**: 32%
- **Clinic UB**: 57%
- **Sant Pau UAB**: 6%
At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.
Financial data
In 2014 there was an increase of more than 160% in income from the capture of public funds and the provision of services.

With regard to expenses, 60% of the IJC's outlay corresponds to staffing. There was an increase in total expenses of 170%, corresponding to the incorporation of new research teams. At this early stage the evolution of income, expenses and investments gives a negative result of €348,557.03.

### Income statement

<table>
<thead>
<tr>
<th>Description</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income from activities</td>
<td>€1,875,004,95</td>
</tr>
<tr>
<td>Services rendered</td>
<td>€381,240,32</td>
</tr>
<tr>
<td>Official subsidies for activities</td>
<td>€1,234,009,72</td>
</tr>
<tr>
<td>Other subsidies, donations…</td>
<td>€259,754,91</td>
</tr>
<tr>
<td><strong>Self-constructed assets</strong></td>
<td></td>
</tr>
<tr>
<td>Supplies</td>
<td>-€504,271,90</td>
</tr>
<tr>
<td>Other income from activity</td>
<td>€7,914,76</td>
</tr>
<tr>
<td><strong>Staff costs</strong></td>
<td>-€1,050,398,36</td>
</tr>
<tr>
<td>Wages and salaries</td>
<td>-€813,338,79</td>
</tr>
<tr>
<td>Social security expenses</td>
<td>-€237,059,57</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td>-€321,616,66</td>
</tr>
<tr>
<td>External services</td>
<td>-€320,066,66</td>
</tr>
<tr>
<td>Taxes</td>
<td>-€50,00</td>
</tr>
<tr>
<td>Losses, depreciation…</td>
<td>€0,00</td>
</tr>
<tr>
<td>Other current period losses</td>
<td>-€1,500,00</td>
</tr>
<tr>
<td><strong>Fixed asset depreciation</strong></td>
<td>-€379,652,53</td>
</tr>
<tr>
<td>IJC Subsidy</td>
<td>€31,095,51</td>
</tr>
<tr>
<td>Other income</td>
<td>€1,238,23</td>
</tr>
<tr>
<td><strong>OPERATING INCOME</strong></td>
<td>-€340,686,00</td>
</tr>
<tr>
<td>Financial income</td>
<td>€1,372,75</td>
</tr>
<tr>
<td>Financial expenses</td>
<td>-€9,598,69</td>
</tr>
<tr>
<td>Subsidy return expenses</td>
<td></td>
</tr>
<tr>
<td>Exchange rate differences</td>
<td>€354,92</td>
</tr>
<tr>
<td>Financial result</td>
<td>-€7,871,02</td>
</tr>
<tr>
<td>Surplus / deficit before tax</td>
<td>-€348,557,02</td>
</tr>
<tr>
<td>Tax on profit</td>
<td>€0,00</td>
</tr>
<tr>
<td><strong>SURPLUS / DEFICIT OF THE FINANCIAL YEAR</strong></td>
<td>-€348,557,02</td>
</tr>
</tbody>
</table>
## Balance Sheet

### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
</tr>
<tr>
<td>Intangible fixed assets</td>
<td>€2.197,592,58</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>€4.157,148,86</td>
</tr>
<tr>
<td>Long-term investments in group and associated entities</td>
<td>€0,00</td>
</tr>
<tr>
<td>Long-term financial investments</td>
<td>€30,979,28</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
</tr>
<tr>
<td>Stock</td>
<td></td>
</tr>
<tr>
<td>Users, sponsors and other debtors from activities</td>
<td>€2,710,437,50</td>
</tr>
<tr>
<td>Other credits with the public administration</td>
<td></td>
</tr>
<tr>
<td>Short-term financial investments</td>
<td></td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€20,020,35</td>
</tr>
<tr>
<td>Cash and others</td>
<td>€1,566,994,00</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>€10,683,172,57</td>
</tr>
</tbody>
</table>

### LIABILITIES

<table>
<thead>
<tr>
<th>Description</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net assets</strong></td>
<td>€4,703,682,48</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td>€3,565,944,75</td>
</tr>
<tr>
<td>Start-up funds</td>
<td>€4,043,656,50</td>
</tr>
<tr>
<td>Special funds</td>
<td></td>
</tr>
<tr>
<td>Profit or loss from previous years</td>
<td>-€129,154,73</td>
</tr>
<tr>
<td>Year profit or loss</td>
<td>-€348,557,02</td>
</tr>
<tr>
<td>Subsidies, donations and legacies</td>
<td>€1,137,737,73</td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>Long-term debt</td>
<td>€1,714,688,37</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>Short-term provisions</td>
<td></td>
</tr>
<tr>
<td>Short-term debt</td>
<td>€3,392,153,46</td>
</tr>
<tr>
<td>Creditors for activities and others</td>
<td>€250,807,79</td>
</tr>
<tr>
<td>Short-term debts with group and associated entities</td>
<td>€56,597,77</td>
</tr>
<tr>
<td>Current tax liabilities and other debts with the public administration</td>
<td></td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€565,242,70</td>
</tr>
<tr>
<td><strong>TOTAL (LIABILITIES + NA)</strong></td>
<td>€10,683,172,57</td>
</tr>
</tbody>
</table>
Evolution of income

2012: €502,014.45
2013: €1,159,986.81
2014: €1,875,004.95
Scientific activity
Research groups

IJC GermansTrias
ALL
MDS
CMPN
NHL ± HIV
MM
CLL
Fe and Cancer
Chromatin

IJC Sant Pau

Stem Cells
ALL infant
AML
BMT
NHL
MM
MDS

IJC Clínic

AML
NHL
BMT
CLL
Thrombosis and Cancer
MM
Animal models: AML, DLBCL
### Research projects

<table>
<thead>
<tr>
<th>IP</th>
<th>Projects 2014</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josep Mª Ribera</td>
<td>ISCIII AES PIS</td>
<td>€98,615,00</td>
</tr>
<tr>
<td>Francesc Sole</td>
<td>ISCIII AES PIS</td>
<td>€134,915,00</td>
</tr>
<tr>
<td>Francesc Sole</td>
<td>SGR AGAUR</td>
<td>€50,000,00</td>
</tr>
<tr>
<td>Laura Palomo</td>
<td>FPU MECD</td>
<td>€68,019,00</td>
</tr>
<tr>
<td>Lorenzo Pasquali</td>
<td>RYC MINECO</td>
<td>€208,600,00</td>
</tr>
<tr>
<td>Marcus Buschbeck</td>
<td>SAF-39749</td>
<td>€41,671,00</td>
</tr>
<tr>
<td>Clara Bueno</td>
<td>ISCIII AES PIS</td>
<td>€134,915,00</td>
</tr>
<tr>
<td>Amaia Etxabe</td>
<td>FPI MINECO</td>
<td>€83,900,00</td>
</tr>
<tr>
<td>Alejandra Sanjuan</td>
<td>MARIE CURIE- REA</td>
<td>€100,000,00</td>
</tr>
<tr>
<td>Alessandra Giorgetti</td>
<td>RYC MINECO</td>
<td>€208,600,00</td>
</tr>
<tr>
<td>Cristina Prieto</td>
<td>ISCIII PFI</td>
<td>€54,000,00</td>
</tr>
<tr>
<td>Clara Bueno</td>
<td>MIQUEL SERVET_ISCIII</td>
<td>€151,043,00</td>
</tr>
<tr>
<td>Clara Bueno</td>
<td>ISCIII AES PIS</td>
<td>€134,915,00</td>
</tr>
<tr>
<td>Alessandra Giorgetti</td>
<td>SAF-43072</td>
<td>€115,571,00</td>
</tr>
<tr>
<td>Pablo Menendez</td>
<td>SAF-43065</td>
<td>€301,060,00</td>
</tr>
<tr>
<td>Pablo Menendez</td>
<td>SGR AGAUR</td>
<td>€44,000,00</td>
</tr>
</tbody>
</table>

**Total**: €1,929,824,00
## Competitive funding granted

<table>
<thead>
<tr>
<th></th>
<th>ICO Germans UAB</th>
<th>Clinic UB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active projects (national)</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>Projects awarded (national)</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Projects tendered (national)</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Active projects (international)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Projects awarded (international)</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Projects tendered (international)</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Projects awarded (public)</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Projects awarded (private)</td>
<td>6</td>
<td>10</td>
</tr>
</tbody>
</table>

|                         | Research networks awarded | 1         |

<table>
<thead>
<tr>
<th>Competitive funding granted (€)</th>
<th>€601.820,00</th>
<th>€1.328.044,00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-competitive funding granted (€)</td>
<td>€32.791,00</td>
<td>€167.500,00</td>
</tr>
<tr>
<td>Sum total competitive and non-competitive overheads granted</td>
<td>€120.364,00</td>
<td>€265.608,00</td>
</tr>
</tbody>
</table>

### Graph

![Graph showing competitive and non-competitive funding granted from 2012 to 2014](graph.png)
The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology's (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called 'Collection of samples from patients with hematologic neoplasms'.

The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.
Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment. It enables new treatments to be tested to prevent, relieve or cure diseases.

Transferability and innovation

The IJC vouches for the transferability of knowledge, and the value of and search for market opportunities, in the broadest terms. As well as being in its own interests, it contributes to society and our country’s progress.

At the present time the IJC has the following patent pending:

**Methods for treating diagnosing and prognosing a haematological malignancy**

Inventor: Ruth Muñoz Risueño

WO 2015/197839

PCT/EP2015/064571
Scientific production
Publications

Indexed articles

Global impact factor

<table>
<thead>
<tr>
<th>Year</th>
<th>Indexed Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>7</td>
</tr>
<tr>
<td>2012</td>
<td>16</td>
</tr>
<tr>
<td>2013</td>
<td>32</td>
</tr>
<tr>
<td>2014</td>
<td>55</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>51,362</td>
</tr>
<tr>
<td>2012</td>
<td>55,792</td>
</tr>
<tr>
<td>2013</td>
<td>175,415</td>
</tr>
<tr>
<td>2014</td>
<td>394,453</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total</th>
<th>FI</th>
<th>Citation Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>394.453</td>
<td>29.567</td>
</tr>
</tbody>
</table>
Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases.

The IJC organises a Doctorate in Hematology, a Master’s degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

In 2014 the following theses were presented at the IJC:

**Citogenetic study of leukemia and myelodysplastic syndromes in different health areas of Catalonia: 1990-2009**
Doctoral student: Isabel Granada (UAB)
Directors: Francesc Solé/Evarist Feliu
EXCELENT CUM LAUDE.
Badalona, June 2014

**Study of molecular profiles of patients with myelodysplastic syndrome**
Doctoral student: Vera Ademà (UAB)
Director: Francesc Solé
Badalona, January 2014
EXCELENT CUM LAUDE.
The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses
4
Scientific conference
1
Scientific seminars
18

MDS GRUP
FRANCESC SOLE
Mar Mallo
Vera Ademà

MPN GROUP
LURDES ZAMORA, BLANCA XICOY
Laura Palomo

GLICOLSILATION GROUP
FUMI YAMAMOTO
Emili Cid

ALL GROUP
JM RIBERA
Eulalia Genescà
Jordi Ribera

IRON GROUP
MAYKA SANCHEZ
Jorge Couso

CHROMATIN GROUP
MARCUS BUSCHBECK
Roberto Malinvemi
Julien Douet
Courses

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, May 2014

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, May 2014

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, June 2014

CUBIMOL. Paper: Cytogenetic and genetic changes in myelodysplastic syndromes.
Speaker: Francesc Sole
Madrid September 2014
Cooperation
Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it focuses on broadening its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations.

At the present time the following institutions are connected with the IJC:
Communication
Communication

The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.

Scientific conference at the Josep Carreras Leukaemia Research Institute

Clínic-UB Campus opening ceremony

Science week, Badalona town council
Upcoming challenges
Upcoming challenges

Start of phase 1 of the new IJC building

In 2014 we were able to complete the building, and phase 1 of the Campus construction was awarded, after a public call for tenders, to the ACR Construction Company, which was responsible, amongst other such buildings, for the biomedical research CIM centre, University of Navarre, Pamplona.

This phase of construction will consist of the installation and equipping of all the common services, the closure of the facades and ceilings and the adaptation of the building for use as a work space, with up to 50% of the available floor space being made available for laboratories on each of the three floors housing them. The rest of the space, potentially useful for laboratories, is being reserved for future expansion.

Mission, vision and values

In 2015 the IJC will have to have a unique and shared ethos, a culture that brings together and reflects the following definitions:

Mission: the IJC's *raison d'être*.

Vision: establishing the IJC's aspirations, the long-term view.

Values: the ethical and functional principles guiding the IJC's culture and daily work.

The IJC aspires to be a model of excellence in public administration.
Annex


The importance of the general practitioner as an information source for patients with hereditary haemochromatosis. The EFAPH, the European Federation of Associations of Patients with Haemochromatosis. Patient Educ Couns. 2014 May 5. PPI: S0738-3991(14)00178-5. doi: 10.1016/j.pec.2014.04.017. [Epub ahead of print] IF: 2,598, Q1D1


Headquarters
C/ Muntaner, 383 3r. 08021
Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report please contact:
comunicacio@carrerasresearch.org

The report can also be downloaded from:
http://www.carrerasresearch.org

Publisher, layout and typesetting
Josep Carreras Leukaemia Research Institute

Photography
Photographic archives of the Josep Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute
Scientific Report IJC 2014